GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » EPS (Basic)

NRXS (Neuraxis) EPS (Basic) : $-1.24 (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis EPS (Basic)?

Neuraxis's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.25. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.24.

Neuraxis's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.25. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.24.

Neuraxis's EPS without NRI for the three months ended in Sep. 2024 was $-0.25. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -1.24.

During the past 3 years, the average EPS without NRI Growth Rate was -63.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Neuraxis's highest 3-Year average EPS without NRI Growth Rate was -63.70% per year. The lowest was -63.70% per year. And the median was -63.70% per year.

Neuraxis EPS (Basic) Historical Data

The historical data trend for Neuraxis's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis EPS (Basic) Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS (Basic)
-0.80 -0.62 -0.90 -4.50

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.38 -0.25 -0.32 -0.42 -0.25

Neuraxis EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Neuraxis's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-14.627-0)/3.252
=-4.50

Neuraxis's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.755-0)/7.172
=-0.24

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuraxis  (AMEX:NRXS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Neuraxis EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Neuraxis's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuraxis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » EPS (Basic)
Comparable Companies
GTBP ALZN VIRI EDSA VYNE ARAV OGEN DOMH TNXP NHWK OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
11611 N. Meridian Street, Suite 330, Carmel, IN, USA
Website
http://www.neuraxis.com
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042